CY1115637T1 - Παραγων ενεργοποιησης για υποδοχεα που ενεργοποιειται απο πολλαπλασιαστη υπεροξυσωματος - Google Patents
Παραγων ενεργοποιησης για υποδοχεα που ενεργοποιειται απο πολλαπλασιαστη υπεροξυσωματοςInfo
- Publication number
- CY1115637T1 CY1115637T1 CY20141100850T CY141100850T CY1115637T1 CY 1115637 T1 CY1115637 T1 CY 1115637T1 CY 20141100850 T CY20141100850 T CY 20141100850T CY 141100850 T CY141100850 T CY 141100850T CY 1115637 T1 CY1115637 T1 CY 1115637T1
- Authority
- CY
- Cyprus
- Prior art keywords
- subcontractor
- activators
- alkoxy
- halogen
- receptors activated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
Abstract
Μία ένωση που αντιπροσωπεύεται με τον ακόλουθο γενικό τύπο (II) ή άλας αυτής, χρησιμοποιείται ως ενεργοποιητής του PPARδ όπου το Ga είναι Ο, CH2 ή τα παρόμοια, το Aa είναι θειαζόλη, οξαζόλη ή θειοφαίνιο που μπορεί να έχει υποκατάστατη όπως μια C1-8αλκύλ, C1-8αλκόξυ, αλογόνο, C1-8αλκύλ υποκατεστημένη με αλογόνο ή τα παρόμοια, το Ba είναι C1-8αλκυλένο ή C2-8αλκενυλένο άλυσος και έκαστο των R1a και R2a ανεξαρτήτως είναι υδρογόνο, C1-8αλκύλ, C1-8αλκόξυ, αλογόνο, C1-8αλκύλ υποκατεστημένη με αλογόνο ή τα παρόμοια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006114561 | 2006-04-18 | ||
EP07742334.1A EP2014652B1 (en) | 2006-04-18 | 2007-04-18 | Activating agent for peroxisome proliferator activated receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115637T1 true CY1115637T1 (el) | 2017-01-04 |
Family
ID=38609637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100850T CY1115637T1 (el) | 2006-04-18 | 2014-10-16 | Παραγων ενεργοποιησης για υποδοχεα που ενεργοποιειται απο πολλαπλασιαστη υπεροξυσωματος |
Country Status (23)
Country | Link |
---|---|
US (2) | US8404726B2 (el) |
EP (1) | EP2014652B1 (el) |
JP (3) | JP5290749B2 (el) |
KR (1) | KR101507173B1 (el) |
CN (2) | CN102643248A (el) |
AU (1) | AU2007239283B2 (el) |
BR (1) | BRPI0710266B8 (el) |
CA (1) | CA2649735C (el) |
CY (1) | CY1115637T1 (el) |
DK (1) | DK2014652T3 (el) |
ES (1) | ES2522291T3 (el) |
HK (1) | HK1135377A1 (el) |
IL (1) | IL194847A (el) |
MX (1) | MX2008013292A (el) |
MY (1) | MY154836A (el) |
NO (1) | NO341476B1 (el) |
NZ (1) | NZ572268A (el) |
PL (1) | PL2014652T3 (el) |
PT (1) | PT2014652E (el) |
RU (1) | RU2435764C2 (el) |
SI (1) | SI2014652T1 (el) |
WO (1) | WO2007119887A1 (el) |
ZA (1) | ZA200809148B (el) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102643248A (zh) | 2006-04-18 | 2012-08-22 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CN104672220B (zh) | 2008-04-15 | 2017-09-22 | 日本化学医药株式会社 | 过氧化物酶体增殖剂活化受体的活化剂 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8513230B2 (en) * | 2010-03-05 | 2013-08-20 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US9303000B2 (en) | 2011-01-17 | 2016-04-05 | Karyopharm Therapeutics Inc. | Olefin containing nuclear transport modulators and uses thereof |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
PL3333164T3 (pl) | 2011-07-29 | 2023-12-18 | Karyopharm Therapeutics Inc. | Modulatory transportu jądrowego zawierające ugrupowanie hydrazydu i ich zastosowania |
EA201490406A1 (ru) | 2011-07-29 | 2014-07-30 | Кариофарм Терапевтикс, Инк. | Модуляторы ядерного транспорта и их применение |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3404027B1 (en) | 2012-05-09 | 2020-03-04 | Biogen MA Inc. | Nuclear transport modulators and uses thereof |
WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
EP2981522A4 (en) * | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | ANTAGONISTS OF PPAR |
CN110183422B (zh) | 2013-06-21 | 2023-07-14 | 卡尔约药物治疗公司 | 核转运调节剂及其用途 |
GB2534052A (en) * | 2013-08-30 | 2016-07-13 | Council Scient Ind Res | Pyrazolochalcones as potential anticancer agents |
DK3180331T3 (da) | 2014-08-15 | 2022-09-12 | Karyopharm Therapeutics Inc | Polymorfer af selinexor |
WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
WO2017004525A1 (en) | 2015-07-02 | 2017-01-05 | The Medical College Of Wisconsin, Inc. | Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors |
PT3359528T (pt) | 2015-10-07 | 2022-04-07 | Salk Inst Biological Studies | Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos |
US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
MA43529A (fr) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics Inc | Modulateurs de transport nucléaire et leurs utilisations |
WO2017180818A1 (en) | 2016-04-13 | 2017-10-19 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
CN111343976A (zh) * | 2017-11-15 | 2020-06-26 | 日本化学药品株式会社 | 过氧化物酶体增殖物应答性受体活化剂 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4956379A (en) | 1990-02-13 | 1990-09-11 | Bristol-Myers Squibb Company | Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
CA2090283A1 (en) | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
GB9426448D0 (en) | 1994-12-30 | 1995-03-01 | Wellcome Found | Process |
WO1996020925A1 (fr) | 1995-01-06 | 1996-07-11 | Toray Industries, Inc. | Derive heterocyclique benzocondense et son utilisation |
CA2171702A1 (en) | 1995-03-14 | 1996-09-15 | Takashi Sohda | Benzofuran compounds and their use |
WO1996035688A1 (fr) | 1995-05-08 | 1996-11-14 | Nippon Chemiphar Co., Ltd. | Derives de 2,4-thiazolidinedione ou d'oxazolidinedione et agent hypoglycemique |
ES2171878T3 (es) | 1996-01-22 | 2002-09-16 | Fujisawa Pharmaceutical Co | Derivados de tiazolilbenzofurano y composiciones farmaceuticas que los contienen. |
AU721452B2 (en) | 1996-02-02 | 2000-07-06 | Merck & Co., Inc. | Antidiabetic agents |
US20020032330A1 (en) | 1996-12-24 | 2002-03-14 | Yutaka Nomura | Propionic acid derivatives |
JP4427825B2 (ja) | 1997-07-24 | 2010-03-10 | アステラス製薬株式会社 | コレステロール低下作用を有する医薬組成物 |
US6589969B1 (en) | 1998-10-16 | 2003-07-08 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
JP4618845B2 (ja) | 1999-06-09 | 2011-01-26 | 杏林製薬株式会社 | ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体 |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
PT1206457E (pt) | 1999-08-27 | 2004-03-31 | Lilly Co Eli | Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars |
PE20011010A1 (es) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
JP2001261674A (ja) | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
JP2001354671A (ja) | 2000-04-14 | 2001-12-25 | Nippon Chemiphar Co Ltd | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
US6787552B2 (en) | 2000-08-11 | 2004-09-07 | Nippon Chemiphar Co., Ltd. | PPAR delta activators |
GB0031109D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
GB0031103D0 (en) | 2000-12-20 | 2001-01-31 | Glaxo Group Ltd | Chemical compounds |
WO2002067912A2 (en) | 2001-02-22 | 2002-09-06 | Smithkline Beecham Corporation | Method for treating ppar gamma mediated diseases or conditions |
US7078422B2 (en) | 2001-03-23 | 2006-07-18 | Nippon Chemiphar Co., Ltd. | Activator for peroxisome proliferator-activated receptor |
GB0111523D0 (en) | 2001-05-11 | 2001-07-04 | Glaxo Group Ltd | Chemical compounds |
CN1330641C (zh) | 2001-08-10 | 2007-08-08 | 日本化学医药株式会社 | 过氧化物酶体增殖剂响应受体δ活化剂 |
IL159886A0 (en) | 2001-08-29 | 2004-06-20 | Warner Lambert Co | Oral antidiabetic agents |
US20030171377A1 (en) * | 2001-08-29 | 2003-09-11 | Bigge Christopher Franklin | Antidiabetic agents |
MXPA04003398A (es) | 2001-10-12 | 2004-11-22 | Nippon Chemiphar Co | Activador para el receptor o activado con el proliferador de peroxisoma. |
JP2003292439A (ja) | 2002-02-04 | 2003-10-15 | Sumitomo Pharmaceut Co Ltd | 新規ピロール誘導体からなるppar活性化剤 |
AU2003217274A1 (en) * | 2002-02-25 | 2003-09-09 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
WO2003099793A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
JPWO2004007439A1 (ja) | 2002-07-10 | 2005-11-10 | 住友製薬株式会社 | ビアリール誘導体 |
US6800655B2 (en) | 2002-08-20 | 2004-10-05 | Sri International | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents |
US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
US20050080115A1 (en) | 2002-10-28 | 2005-04-14 | Lone Jeppesen | Novel compounds, their preparation and use |
JP2006514069A (ja) | 2003-01-06 | 2006-04-27 | イーライ リリー アンド カンパニー | Ppar調節因子としての融合複素環式誘導体 |
EP1585733A1 (en) | 2003-01-06 | 2005-10-19 | Eli Lilly And Company | Heterocyclic ppar modulators |
EP1583754A1 (en) * | 2003-01-06 | 2005-10-12 | Eli Lilly And Company | Thiophene derivative ppar modulators |
WO2004071509A1 (ja) | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | オリゴデンドロサイト分化促進剤 |
TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
US20070054902A1 (en) | 2003-12-02 | 2007-03-08 | Shionogi & Co., Ltd. | Isoxazole derivatives as peroxisome proliferator-activated receptors agonists |
GB0403148D0 (en) | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
FR2869611B1 (fr) | 2004-05-03 | 2006-07-28 | Merck Sante Soc Par Actions Si | Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |
WO2005115384A2 (en) | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
WO2006125324A1 (en) | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
AU2006266711A1 (en) | 2005-07-06 | 2007-01-11 | Nippon Chemiphar Co., Ltd. | Activator of peroxisome proliferator activated receptor delta |
CN102643248A (zh) | 2006-04-18 | 2012-08-22 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
WO2008016175A1 (fr) | 2006-08-03 | 2008-02-07 | Nippon Chemiphar Co., Ltd. | Agent activant de récepteur activé par les proliférateurs des peroxysomes |
-
2007
- 2007-04-18 CN CN2012100286090A patent/CN102643248A/zh active Pending
- 2007-04-18 CN CN2007800221905A patent/CN101466687B/zh active Active
- 2007-04-18 SI SI200731540T patent/SI2014652T1/sl unknown
- 2007-04-18 JP JP2008511032A patent/JP5290749B2/ja not_active Expired - Fee Related
- 2007-04-18 RU RU2008145505/04A patent/RU2435764C2/ru active
- 2007-04-18 ZA ZA200809148A patent/ZA200809148B/xx unknown
- 2007-04-18 DK DK07742334.1T patent/DK2014652T3/da active
- 2007-04-18 PL PL07742334T patent/PL2014652T3/pl unknown
- 2007-04-18 US US12/297,436 patent/US8404726B2/en active Active
- 2007-04-18 NZ NZ572268A patent/NZ572268A/en not_active IP Right Cessation
- 2007-04-18 AU AU2007239283A patent/AU2007239283B2/en not_active Ceased
- 2007-04-18 KR KR1020087028047A patent/KR101507173B1/ko active IP Right Grant
- 2007-04-18 BR BRPI0710266A patent/BRPI0710266B8/pt not_active IP Right Cessation
- 2007-04-18 ES ES07742334.1T patent/ES2522291T3/es active Active
- 2007-04-18 WO PCT/JP2007/058899 patent/WO2007119887A1/ja active Application Filing
- 2007-04-18 MX MX2008013292A patent/MX2008013292A/es active IP Right Grant
- 2007-04-18 PT PT77423341T patent/PT2014652E/pt unknown
- 2007-04-18 EP EP07742334.1A patent/EP2014652B1/en active Active
- 2007-04-18 CA CA2649735A patent/CA2649735C/en active Active
-
2008
- 2008-10-17 MY MYPI20084157A patent/MY154836A/en unknown
- 2008-10-22 IL IL194847A patent/IL194847A/en active IP Right Grant
- 2008-11-18 NO NO20084856A patent/NO341476B1/no not_active IP Right Cessation
-
2009
- 2009-12-16 HK HK09111822.2A patent/HK1135377A1/xx not_active IP Right Cessation
-
2012
- 2012-12-21 JP JP2012279230A patent/JP5782016B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-12 US US13/765,540 patent/US20130217734A1/en not_active Abandoned
-
2014
- 2014-10-16 CY CY20141100850T patent/CY1115637T1/el unknown
-
2015
- 2015-03-24 JP JP2015060817A patent/JP6049791B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115637T1 (el) | Παραγων ενεργοποιησης για υποδοχεα που ενεργοποιειται απο πολλαπλασιαστη υπεροξυσωματος | |
DE50311885D1 (de) | Kohlenstoffhaltiges Material | |
CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
DOP2006000045A (es) | Derivados del (1,5-difenil-1h-pirazol-3-il oxadiazol, su preparacion y su aplicacion en terapeutica | |
CY1120477T1 (el) | Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων | |
CY1111428T1 (el) | Μεθοδος για τη συνθεση της 5-(μεθυλ-1η-ιμιδαζολ-1-υλο)-3-(τριφθορομεθυλο)-βενζολαμινης | |
AR057914A1 (es) | Compuestos organicos de azufre y su uso | |
BR0016067A (pt) | Oxazóis substituìdos e derivados tiazóis como ativadores de hppar alfa | |
PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
AR078520A1 (es) | Compuesto heterociclico y su uso para el control de una plaga de artro-podos | |
BRPI0909731A2 (pt) | derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização | |
DE602005026306D1 (de) | Carbazolderivat und davon gebrauch machende organische lichtemittierende vorrichtung | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
CO6160235A2 (es) | Isoxazolinas insecticidas | |
AR044695A1 (es) | Derivados de azolidina, utiles como herbicidas. | |
TW200643139A (en) | π-conjugated compound having cardo structure, process for preparing same and use of same | |
ECSP088149A (es) | 3-acilaminobenzanilidas insecticidas | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
ECSP088479A (es) | Derivados de oxadiazol | |
TW200602456A (en) | Anthracene compound and organic electroluminescent device including the anthracene compound | |
AR057088A1 (es) | Compuestos quimicos | |
EA200801365A1 (ru) | Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины | |
AR066603A1 (es) | Derivados de arilamida pirimidona | |
TW200700532A (en) | Aromatic amine derivative and organic electroluminescence element using the same | |
PE20020906A1 (es) | Inhibidores de peptido-deformilasa |